• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Jessica Allegretti Explains Rebyota’s Mechanism of Action for the Prevention of Recurrent CDI

Video

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, explained the mechanism of action for Rebyota, the first fecal transplant therapy approved by the FDA for the prevention of recurrent Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.

Rebyota was recently approved as the first live microbiome-based therapeutic for the prevention of recurrent Clostridioides difficile infection (CDI) and works by restoring the functionality of a patient’s microbiome after antibiotic treatment, said Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital.

Transcript

Can you explain the mechanism of action for Rebyota and the significance of its FDA approval as the first fecal transplant therapy for the prevention of recurrent CDI?

So, it's certainly very exciting that Rebyota was just approved. This is going to be the first live microbiome-based therapeutic that we have—we generally call these products LPBs [live biotherapeutic products]. This is a rectally administered therapy that's meant to be done in the office or in the hospital setting. And again, it's indicated for the prevention of recurrent CDI.

What we know is that with CDI, the patient took antibiotics, which likely led to this infection, and then multiple rounds of antibiotics to treat. And so you've essentially ablated your gut microbiome. Therapies such as Rebyota are really meant to replace the ecology of your gut microbiome, and restore functionality of your microbiome so that you can be able to overcome this infection.

Related Videos
Dr Michael Morse, Duke University
Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Ross Margulies, health care attorney and partner at Foley Hoag LLP.
Pat Van Burkleo
dr robert sidbury
dr mitzi joi williams
dr lawrence eichenfield
dr krystyn van vliet
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.